Published in Endocr Relat Cancer on March 01, 2002
Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer. Proc Natl Acad Sci U S A (2006) 1.78
Is PTEN loss associated with clinical outcome measures in human prostate cancer? Br J Cancer (2008) 1.66
Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer. Mol Cancer Ther (2008) 1.59
New developments in the medical management of prostate cancer. Mayo Clin Proc (2010) 1.41
Androgen receptor signaling and mutations in prostate cancer. Asian J Androl (2010) 1.27
Molecular mechanisms of castration-resistant prostate cancer progression. Future Oncol (2009) 1.26
CXCR4 expression in prostate cancer progenitor cells. PLoS One (2012) 1.25
Apoptosis evasion: the role of survival pathways in prostate cancer progression and therapeutic resistance. J Cell Biochem (2006) 1.22
5α-reductase type 3 expression in human benign and malignant tissues: a comparative analysis during prostate cancer progression. Prostate (2010) 1.15
Diosgenin, a steroidal saponin, inhibits migration and invasion of human prostate cancer PC-3 cells by reducing matrix metalloproteinases expression. PLoS One (2011) 1.10
Inhibition of monoamine oxidase A promotes secretory differentiation in basal prostatic epithelial cells. Differentiation (2008) 1.03
Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers. Proc Natl Acad Sci U S A (2003) 1.02
AKR1C3 overexpression may serve as a promising biomarker for prostate cancer progression. Diagn Pathol (2014) 1.01
New insights into the mechanisms of green tea catechins in the chemoprevention of prostate cancer. Nutr Cancer (2011) 0.98
8-Hydroxyquinolines: a review of their metal chelating properties and medicinal applications. Drug Des Devel Ther (2013) 0.97
Impact of stroma on the growth, microcirculation, and metabolism of experimental prostate tumors. Neoplasia (2007) 0.97
Mechanisms of acquired androgen independence during arsenic-induced malignant transformation of human prostate epithelial cells. Environ Health Perspect (2006) 0.94
Small carboxyl-terminal domain phosphatase 2 attenuates androgen-dependent transcription. EMBO J (2006) 0.94
A role for the androgen-receptor in clinically localized and advanced prostate cancer. Best Pract Res Clin Endocrinol Metab (2008) 0.94
Inhibition of apoptosis in prostate cancer cells by androgens is mediated through downregulation of c-Jun N-terminal kinase activation. Neoplasia (2008) 0.91
Genome-wide impact of androgen receptor trapped clone-27 loss on androgen-regulated transcription in prostate cancer cells. Cancer Res (2009) 0.90
Enoxacin inhibits growth of prostate cancer cells and effectively restores microRNA processing. Epigenetics (2013) 0.89
Cofilin drives cell-invasive and metastatic responses to TGF-β in prostate cancer. Cancer Res (2014) 0.89
Spontaneous cancer-stromal cell fusion as a mechanism of prostate cancer androgen-independent progression. PLoS One (2012) 0.88
Acquisition of androgen independence by human prostate epithelial cells during arsenic-induced malignant transformation. Environ Health Perspect (2005) 0.88
Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models. Int J Oncol (2012) 0.87
Androgen deprivation induces phenotypic plasticity and promotes resistance to molecular targeted therapy in a PTEN-deficient mouse model of prostate cancer. Carcinogenesis (2014) 0.86
Stromal androgen receptor in prostate development and cancer. Am J Pathol (2014) 0.85
The PPARγ ligand ciglitazone regulates androgen receptor activation differently in androgen-dependent versus androgen-independent human prostate cancer cells. Exp Cell Res (2010) 0.83
A peptide against soluble guanylyl cyclase α1: a new approach to treating prostate cancer. PLoS One (2013) 0.83
Morusin induces cell death through inactivating STAT3 signaling in prostate cancer cells. Am J Cancer Res (2014) 0.82
14-3-3{eta} Amplifies Androgen Receptor Actions in Prostate Cancer. Clin Cancer Res (2009) 0.82
Dominant-negative androgen receptor inhibition of intracrine androgen-dependent growth of castration-recurrent prostate cancer. PLoS One (2012) 0.82
DHEA metabolism in prostate: For better or worse? Mol Cell Endocrinol (2008) 0.82
Androgen receptor non-nuclear regulation of prostate cancer cell invasion mediated by Src and matriptase. Oncotarget (2015) 0.81
STAMP2 increases oxidative stress and is critical for prostate cancer. EMBO Mol Med (2015) 0.81
TRPM8 channel as a novel molecular target in androgen-regulated prostate cancer cells. Oncotarget (2015) 0.81
Caveolae contribute to the apoptosis resistance induced by the alpha(1A)-adrenoceptor in androgen-independent prostate cancer cells. PLoS One (2009) 0.81
Prostate cancer epigenetics: a review on gene regulation. Gene Regul Syst Bio (2007) 0.81
Curcumin Inhibits Prostate Cancer Bone Metastasis by Up-Regulating Bone Morphogenic Protein-7 in Vivo. J Cancer Ther (2014) 0.80
Enhanced sensitivity to androgen withdrawal due to overexpression of interleukin-6 in androgen-dependent human prostate cancer LNCaP cells. Br J Cancer (2009) 0.80
Somatostatin derivative (smsDX) targets cellular metabolism in prostate cancer cells after androgen deprivation therapy. PLoS One (2013) 0.79
Exposure to ethinylestradiol during prenatal development and postnatal supplementation with testosterone causes morphophysiological alterations in the prostate of male and female adult gerbils. Int J Exp Pathol (2011) 0.79
TGF-β Effects on Prostate Cancer Cell Migration and Invasion Require FosB. Prostate (2016) 0.78
The importance of non-nuclear AR signaling in prostate cancer progression and therapeutic resistance. Cell Signal (2016) 0.77
COP9 subunits 4 and 5 target soluble guanylyl cyclase α1 and p53 in prostate cancer cells. Mol Endocrinol (2014) 0.76
Crosstalk of the Androgen Receptor with Transcriptional Collaborators: Potential Therapeutic Targets for Castration-Resistant Prostate Cancer. Cancers (Basel) (2017) 0.75
Androgen receptor regulates SRC expression through microRNA-203. Oncotarget (2016) 0.75
Apoptotic Pathways Linked to Endocrine System as Potential Therapeutic Targets for Benign Prostatic Hyperplasia. Int J Mol Sci (2016) 0.75
Human Prostate Cancer Hallmarks Map. Sci Rep (2016) 0.75
Differential expression of AP-1 transcription factors in human prostate LNCaP and PC-3 cells: role of Fra-1 in transition to CRPC status. Mol Cell Biochem (2017) 0.75
Targeting the mercapturic acid pathway and vicenin-2 for prevention of prostate cancer. Biochim Biophys Acta (2017) 0.75
The development of androgen-independent prostate cancer. Nat Rev Cancer (2001) 11.88
Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med (1998) 6.84
Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol (1999) 4.85
A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med (1999) 4.20
Hereditary prostate cancer: epidemiologic and clinical features. J Urol (1993) 3.86
Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res (1994) 3.43
Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med (2000) 3.26
Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci U S A (1994) 3.24
The possible influence of temporal factors in androgenic responsiveness of urogenital tissue recombinants from wild-type and androgen-insensitive (Tfm) mice. J Exp Zool (1978) 2.53
Glutathione S-transferases, structure, regulation, and therapeutic implications. J Biol Chem (1993) 2.23
Activation of the human androgen receptor through a protein kinase A signaling pathway. J Biol Chem (1996) 2.15
Etiology and disease process of benign prostatic hyperplasia. Prostate Suppl (1989) 2.12
Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res (1995) 1.98
Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate (1996) 1.91
Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol Endocrinol (1997) 1.90
Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res (1991) 1.87
Interactions between adult human prostatic epithelium and rat urogenital sinus mesenchyme in a tissue recombination model. Differentiation (1998) 1.86
Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol (1993) 1.73
Mechanisms of androgen receptor activation and function. J Steroid Biochem Mol Biol (1999) 1.68
The role of steroid hormones in prostate carcinogenesis. J Natl Cancer Inst Monogr (2000) 1.68
Role of mesenchymal-epithelial interactions in normal and abnormal development of the mammary gland and prostate. Cancer (1994) 1.64
What might a stromal response mean to prostate cancer progression? Cancer Metastasis Rev (1999) 1.62
Hormone-induced morphogenesis and growth: role of mesenchymal-epithelial interactions. Recent Prog Horm Res (1983) 1.60
The prostate: a target for carcinogenicity of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) derived from cooked foods. Cancer Res (1997) 1.57
The biology of hormone refractory prostate cancer. Why does it develop? Urol Clin North Am (1999) 1.55
Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells. Cancer Res (2001) 1.54
Antagonistic effect of androgen on prostatic cell death. Prostate (1984) 1.36
Endometrial stromal cells regulate epithelial cell growth in vitro: a new co-culture model. Hum Reprod (2001) 1.34
Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer. Cancer Res (2001) 1.32
CG island methylation changes near the GSTP1 gene in prostatic carcinoma cells detected using the polymerase chain reaction: a new prostate cancer biomarker. Cancer Epidemiol Biomarkers Prev (1997) 1.26
Protection against 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b]pyridine cytotoxicity and DNA adduct formation in human prostate by glutathione S-transferase P1. Cancer Res (2001) 1.22
Rational basis for Trk inhibition therapy for prostate cancer. Prostate (2000) 1.22
Mesenchyme-induced changes in the neoplastic characteristics of the Dunning prostatic adenocarcinoma. Cancer Res (1991) 1.20
Expression of bcl-2 and the progression of human and rodent prostatic cancers. Clin Cancer Res (1996) 1.16
Malignant transformation of human prostatic epithelium is associated with the loss of androgen receptor immunoreactivity in the surrounding stroma. Clin Cancer Res (1999) 1.15
Role of androgens in prostatic cancer. Vitam Horm (1994) 1.14
Localization of type 5 17beta-hydroxysteroid dehydrogenase, 3beta-hydroxysteroid dehydrogenase, and androgen receptor in the human prostate by in situ hybridization and immunocytochemistry. Endocrinology (1999) 1.14
Stromal cells from human benign prostate hyperplasia produce a growth-inhibitory factor for LNCaP prostate cancer cells, identified as interleukin-6. Int J Cancer (1996) 1.13
Growth factors and epithelial-stromal interactions in prostate cancer development. Int Rev Cytol (2000) 1.12
Versican accumulation in human prostatic fibroblast cultures is enhanced by prostate cancer cell-derived transforming growth factor beta1. Cancer Res (2001) 1.11
Normal development and carcinogenesis of the prostate. A unifying hypothesis. Ann N Y Acad Sci (1996) 1.10
Smooth muscle-epithelial interactions in normal and neoplastic prostatic development. Acta Anat (Basel) (1996) 1.09
Restoration of normal morphology and estrogen responsiveness in cultured vaginal and uterine epithelia transplanted with stroma. Proc Natl Acad Sci U S A (1986) 1.06
Tissue architecture and breast cancer: the role of extracellular matrix and steroid hormones. Endocr Relat Cancer (2000) 1.06
Genetic instability coupled to clonal selection as a mechanism for tumor progression in the Dunning R-3327 rat prostatic adenocarcinoma system. Cancer Res (1982) 1.04
Effect of normal endometrial stroma on growth and differentiation in Ishikawa endometrial adenocarcinoma cells. Cancer Res (2002) 1.03
Garbage catastrophe theory of aging: imperfect removal of oxidative damage? Redox Rep (2001) 1.02
Cadmium and prostate cancer. J Toxicol Environ Health (1994) 1.01
Intratissular androgens in benign prostatic hyperplasia and prostatic cancer. J Steroid Biochem (1986) 1.00
Suppressor gene alterations in the colorectal adenoma-carcinoma sequence. J Cell Biochem Suppl (1992) 0.98
Human prostate cancer model: roles of growth factors and extracellular matrices. J Cell Biochem Suppl (1992) 0.98
Steroid sulfate sulfatase in human benign prostatic hyperplasia: characterization and quantification of the enzyme in epithelium and stroma. J Steroid Biochem (1989) 0.98
2-difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice. Cancer Res (2001) 0.97
Chemoprevention of hormone-dependent prostate cancer in the Wistar-Unilever rat. Eur Urol (1999) 0.96
Hormone regulation of human prostate in organ culture. Cancer Res (1993) 0.96
Neonatal estrogen stimulates proliferation of periductal fibroblasts and alters the extracellular matrix composition in the rat prostate. Endocrinology (1999) 0.96
Morphostats: a missing concept in cancer biology. Cancer Epidemiol Biomarkers Prev (2001) 0.95
Clonal growth of human prostatic epithelial cells is stimulated by fibroblasts. Prostate (1989) 0.95
Estrogen and progestin receptors in the reproductive tract of male and female primates. Biol Reprod (1990) 0.95
Eat to live, not live to eat. Nutrition (2000) 0.95
Crucial role of cytokines in sex steroid formation in normal and tumoral tissues. Mol Cell Endocrinol (2001) 0.94
Skin fibroblasts obtained from cancer patients display foetal-like migratory behaviour on collagen gels. J Cell Sci (1985) 0.94
Selective interactions between prostate fibroblast and epithelial cells in co-culture maintain the BPH phenotype. Urol Int (1998) 0.92
Prostatic epithelium inhibiting factor (PEIF): organ specificity and production by prostatic fibroblasts. Urol Res (1987) 0.88
Chemoprevention of spontaneous tumorigenesis in nullizygous p53-deficient mice by dehydroepiandrosterone and its analog 16alpha-fluoro-5-androsten-17-one. Carcinogenesis (1997) 0.87
Immunolocalization of the keratinocyte growth factor in benign and neoplastic human prostate and its relation to androgen receptor. Prostate (1999) 0.87
The androgen receptor status of neuroendocrine cells in human benign and malignant prostatic tissue. Cancer Res (1993) 0.86
Benign hyperplasia of the human prostate is associated with tissue enrichment in chondroitin sulphate of wide size distribution. Prostate (2000) 0.85
Oxidative stress in chemoprevention trials. Urology (2001) 0.85
Stromal inhibition of prostatic epithelial cell proliferation not mediated by transforming growth factor beta. Br J Cancer (1995) 0.84
Regulation of macrophage dehydroepiandrosterone sulfate metabolism by inflammatory cytokines. Endocrinology (1994) 0.83
Hormonal carcinogenesis and environmental influences: background and overview. Prog Clin Biol Res (1996) 0.82
Lessons to be learned from the androgen receptor. Eur J Dermatol (2001) 0.81
Chromosomal changes associated with progression of the Dunning R-3327 rat prostatic adenocarcinoma system. Cancer Res (1982) 0.80
Mechanism of cancer preventive action of DHEA. Role of glucose-6-phosphate dehydrogenase. Ann N Y Acad Sci (1995) 0.80
Quantitative assessment of endogenous testicular and adrenal sex steroids and of steroid metabolizing enzymes in untreated human prostatic cancerous tissue. J Steroid Biochem (1988) 0.80
Androgen independence of primary epithelial cultures of the prostate is associated with a down-regulation of androgen receptor gene expression. Prostate (1996) 0.79
Development of a new in vitro model for the study of benign prostatic hyperplasia. Prostate Suppl (2000) 0.78
Partial androgen insensitivity caused by an androgen receptor mutation at amino acid 907 (Gly-->Arg) that results in decreased ligand binding affinity and reduced androgen receptor messenger ribonucleic acid levels. J Clin Endocrinol Metab (1996) 0.78
On some general concepts in oncology with special reference to Hodgkin's disease. Int J Radiat Oncol Biol Phys (1983) 0.78
Human prostatic dehydroepiandrosterone sulfate sulfatase. Steroids (1973) 0.77
Effect of antiandrogen and/or antiestrogen blockade on human prostate epithelial and stromal cell protein synthesis. J Steroid Biochem (1986) 0.77
Conversion of lytic to persistent alphavirus infection by the bcl-2 cellular oncogene. Nature (1993) 4.81
KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science (1995) 3.97
Macrophage role in the anti-prostate cancer response to one class of antiangiogenic agents. J Natl Cancer Inst (1998) 3.13
Response of glandular versus basal rat ventral prostatic epithelial cells to androgen withdrawal and replacement. Prostate (1987) 2.70
Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology (1988) 2.38
Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. Cancer Res (1991) 2.08
Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate (1996) 1.91
Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res (1990) 1.82
Expression of transforming growth factor-beta in the rat ventral prostate during castration-induced programmed cell death. Mol Endocrinol (1989) 1.82
Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma. Cancer Res (1981) 1.80
Implication of cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res (1995) 1.68
Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. Prostate (1986) 1.65
Activation of programmed cell death by recombinant human tumor necrosis factor plus topoisomerase II-targeted drugs in L929 tumor cells. J Natl Cancer Inst (1991) 1.57
Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells. Cancer Res (2001) 1.54
The role of calcium, pH, and cell proliferation in the programmed (apoptotic) death of androgen-independent prostatic cancer cells induced by thapsigargin. Cancer Res (1994) 1.53
Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen. Cancer Res (1997) 1.51
Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss. Cancer Res (1996) 1.50
Paracrine regulation of apoptosis by steroid hormones in the male and female reproductive system. Cell Death Differ (2001) 1.43
Antagonistic effect of androgen on prostatic cell death. Prostate (1984) 1.36
Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clin Cancer Res (1997) 1.32
Clinical evidence for and implications of the multistep development of prostate cancer. J Urol (1990) 1.32
Early cell motility changes associated with an increase in metastatic ability in rat prostatic cancer cells transfected with the v-Harvey-ras oncogene. Cancer Res (1988) 1.32
Cell proliferation, DNA repair, and p53 function are not required for programmed death of prostatic glandular cells induced by androgen ablation. Proc Natl Acad Sci U S A (1993) 1.29
Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen. Cancer Res (1998) 1.28
CD44 is a metastasis suppressor gene for prostatic cancer located on human chromosome 11p13. Cancer Res (1997) 1.25
Decreased expression of E-cadherin in the progression of rat prostatic cancer. Cancer Res (1992) 1.23
Genomic organization of the human KAI1 metastasis-suppressor gene. Genomics (1997) 1.23
Activation of a Ca2+-Mg2+-dependent endonuclease as an early event in castration-induced prostatic cell death. Prostate (1988) 1.22
Rational basis for Trk inhibition therapy for prostate cancer. Prostate (2000) 1.22
Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers. Cancer Res (1997) 1.20
Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555). Cancer Res (1999) 1.19
Epidermal growth factor-mediated apoptosis of MDA-MB-468 human breast cancer cells. Cancer Res (1994) 1.19
Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models. Prostate (2001) 1.17
Epidemiologic evidence regarding predisposing factors to prostate cancer. Prostate (1990) 1.17
Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia. J Urol (1999) 1.16
Expression of bcl-2 and the progression of human and rodent prostatic cancers. Clin Cancer Res (1996) 1.16
Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587). Clin Cancer Res (1998) 1.12
Programmed death of nonproliferating androgen-independent prostatic cancer cells. Cancer Res (1991) 1.12
Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration. Prostate (1989) 1.11
Linomide inhibits angiogenesis, growth, metastasis, and macrophage infiltration within rat prostatic cancers. Cancer Res (1995) 1.11
Animal models of the hormone-sensitive and -insensitive prostatic adenocarcinomas, Dunning R-3327-H, R-3327-HI, and R-3327-AT. Cancer Res (1978) 1.11
Methylation of the CD44 metastasis suppressor gene in human prostate cancer. Cancer Res (1999) 1.11
Defining a common region of deletion at 13q21 in human cancers. Genes Chromosomes Cancer (2001) 1.11
A supramicromolar elevation of intracellular free calcium ([Ca(2+)](i)) is consistently required to induce the execution phase of apoptosis. Cell Death Differ (2002) 1.08
Prostate-specific membrane antigen (PSMA) enzyme activity is elevated in prostate cancer cells. Prostate (2000) 1.07
Design, synthesis, and pharmacological evaluation of thapsigargin analogues for targeting apoptosis to prostatic cancer cells. J Med Chem (2001) 1.07
Effect of transforming growth factor-beta 1 on proliferation and death of rat prostatic cells. Endocrinology (1990) 1.07
The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer. Prostate (1984) 1.06
Combinatorial androgen receptor targeted therapy for prostate cancer. Endocr Relat Cancer (2006) 1.05
Prostate tumor biology and cell kinetics--theory. Urology (1981) 1.05
Genetic instability coupled to clonal selection as a mechanism for tumor progression in the Dunning R-3327 rat prostatic adenocarcinoma system. Cancer Res (1982) 1.04
Assessment and validation of a microinjection method for kinetic analysis of [Ca2+]i in individual cells undergoing apoptosis. Cell Calcium (1999) 1.03
Suppression of the tumorigenicity of prostatic cancer cells by gene(s) located on human chromosome 19p13.1-13.2. Prostate (1999) 1.02
Deletion at 13q21 is associated with aggressive prostate cancers. Cancer Res (2000) 1.02
Genetic control of resistance to chemically induced mammary adenocarcinogenesis in the rat. Cancer Res (1986) 1.02
Localization of metastasis suppressor gene(s) for prostatic cancer to the short arm of human chromosome 11. Cancer Res (1992) 1.01
Identification of a cellular receptor for transforming growth factor-beta in rat ventral prostate and its negative regulation by androgens. Endocrinology (1988) 0.99
Thapsigargin induces a calmodulin/calcineurin-dependent apoptotic cascade responsible for the death of prostatic cancer cells. Prostate (2000) 0.98
CEP-751 inhibits TRK receptor tyrosine kinase activity in vitro exhibits anti-tumor activity. Int J Cancer (1997) 0.98
The characterization of a newly identified, highly metastatic variety of Dunning R 3327 rat prostatic adenocarcinoma system: the MAT LyLu tumor. Invest Urol (1981) 0.98
Mechanism and role of growth arrest in programmed (apoptotic) death of prostatic cancer cells induced by thapsigargin. Prostate (1997) 0.98
Thapsigargin analogues for targeting programmed death of androgen-independent prostate cancer cells. Bioorg Med Chem (1999) 0.98
Metastasis suppression by the standard CD44 isoform does not require the binding of prostate cancer cells to hyaluronate. Cancer Res (1998) 0.98
Stimulation of human prostatic carcinoma tumor growth in athymic mice and control of migration in culture by extracellular matrix. Int J Cancer (1992) 0.98
Androgenic sensitivity of the gubernaculum testis: evidence for hormonal/mechanical interactions in testicular descent. J Urol (1982) 0.97
Pan-trk inhibition decreases metastasis and enhances host survival in experimental models as a result of its selective induction of apoptosis of prostate cancer cells. Clin Cancer Res (2001) 0.97
Antiangiogenic effects of the quinoline-3-carboxamide linomide. Cancer Res (1993) 0.97
Oncogene expression in prostate cancer: Dunning R3327 rat dorsal prostatic adenocarcinoma system. Prostate (1988) 0.95
Reduction of human prostate tumor vascularity by the alpha1-adrenoceptor antagonist terazosin. Prostate (2001) 0.95
Response of rat and human prostatic cancers to the novel 5 alpha-reductase inhibitor, SK&F 105657. Prostate (1992) 0.95
Differential gene regulation during programmed death (apoptosis) versus proliferation of prostatic glandular cells induced by androgen manipulation. Endocrinology (1993) 0.94
Pathophysiology and significance of malabsorption after Roux-en-Y reconstruction. Surgery (1977) 0.94
Prostatic structure and function in relation to the etiology of prostatic cancer. Prostate (1983) 0.94
The antitumor effects of the quinoline-3-carboxamide linomide on Dunning R-3327 rat prostatic cancers. Cancer Res (1992) 0.94
"Thymineless" death in androgen-independent prostatic cancer cells. Biochem Biophys Res Commun (1989) 0.93
Differential suppression of mammary and prostate cancer metastasis by human chromosomes 17 and 11. Cancer Res (1994) 0.93
Induction of programmed death/apoptosis androgen-dependent mouse mammary tumor cell line (Shionogi Carcinoma 115) by androgen withdrawal. Jpn J Cancer Res (1995) 0.93
The aging ACI/Seg versus Copenhagen male rat as a model system for the study of prostatic carcinogenesis. Cancer Res (1984) 0.92
Quantal relationship between prostatic dihydrotestosterone and prostatic cell content: critical threshold concept. Prostate (1987) 0.91
The role of prostate-specific antigen in the clinical evaluation of prostatic disease. BJU Int (2004) 0.91
Therapeutic implications of enhanced G(0)/G(1) checkpoint control induced by coculture of prostate cancer cells with osteoblasts. Cancer Res (2001) 0.91
Prostate cancer--biology of metastasis and its clinical implications. World J Urol (1996) 0.90
Molecular and cellular changes associated with the acquisition of metastatic ability by prostatic cancer cells. Prostate (1994) 0.90
Molecular advances in prostate cancer. Curr Opin Oncol (1997) 0.90
Experimental intravesical therapy for superficial transitional cell carcinoma in a rat bladder tumor model. J Urol (1991) 0.89
Enzymatic activation of prodrugs by prostate-specific antigen: targeted therapy for metastatic prostate cancer. Cancer J Sci Am (1998) 0.89
Characterization of an N-methyl-N-nitrosourea-induced autochthonous rat bladder cancer model. Cancer Res (1990) 0.89
Cyclic AMP-dependent control of the rat hepatic glutathione disulfide-sulfhydryl ratio. Biochim Biophys Acta (1977) 0.89
Association of glyceraldehyde-3-phosphate dehydrogenase expression with cell motility and metastatic potential of rat prostatic adenocarcinoma. Cancer Res (1993) 0.89
Prostatic involution in rats induced by a novel 5 alpha-reductase inhibitor, SK&F 105657: role for testosterone in the androgenic response. Endocrinology (1992) 0.88
Suppression of metastasis of rat prostatic cancer by introducing human chromosome 8. Cancer Res (1994) 0.87
Genetic factors and suppression of metastatic ability of prostatic cancer. Cancer Res (1991) 0.87
Control of prostate growth. Urology (1981) 0.87
Hormonally responsive versus unresponsive progression of prostatic cancer to antiandrogen therapy as studied with the Dunning R-3327-AT and -G rat adenocarcinomas. Cancer Res (1982) 0.87
Human prostatic cancer cells are sensitive to programmed (apoptotic) death induced by the antiangiogenic agent linomide. Cancer Res (1995) 0.87
Location of KAI1 on the short arm of human chromosome 11 and frequency of allelic loss in advanced human prostate cancer. Prostate (1997) 0.87
Unusual androgen sensitivity of the androgen-independent Dunning R-3327-G rat prostatic adenocarcinoma: androgen effect on tumor cell loss. Cancer Res (1982) 0.87
Localization and physical mapping of the prostate-specific membrane antigen (PSM) gene to human chromosome 11. Genomics (1995) 0.87